This page contains a Flash digital edition of a book.
vaccination routines. Impacts


Where survey respondents identifi ed the impact of an outbreak of PD on their busi- ness ‘mortality’, ‘growth’ and ‘downgrades at processing’ ranked as the three largest fac- tors. Financial values were not provided but, with initial mortality levels of up to 40% and growth rates of surviving fi sh signifi cantly affected, the direct and consequential cost of an outbreak of PD can be large. Many of the improvements put in place by vaccination should result in a reduction in mortality as well as greatly limiting the dam- aging effect of the disease in the growing-on stages. As has been reported before, through PD Monitor, the number of vaccinated fi sh showing clinical signs of PD is extremely low. In 2010 several million vaccinated fi sh were stocked into a high-risk area of the Shetlands and these are continuing to record no clinical outbreak throughout the monitoring process. The availability of newer vaccines and sup- port packages has been a strong incentive to adopt an up-to-date programme. The poten- tial impact of an outbreak remains signifi cant and feedback to the company from producers, through the survey and general contact, is that a long term strategy of vaccination and monitoring will be a fi rst choice option for salmon producers looking to stabilise and improve fi sh health and performance going forward.


Producers taking part in the survey were www.fishfarmer-magazine.com


included in a lucky draw. The winner of the Patagonia Shelter Stone jacket, as notifi ed by the company, was David Brown from Scottish Sea Farms, Ollaberry, Shetland. Producers who would like to discuss Nor- vax® Compact PD vaccination programmes should contact Dafydd Morris at MSD Ani- mal Health on 03700 6033804.


In June this year, Intervet/Schering-Plough Animal Health was renamed MSD Animal Health, a subsidiary of Merck & Co, Inc. These changes also reinforce the commitment of the company to supporting the strategic development of the animal health business. The name change has been communicated to all veterinary clients in the UK. It may be a short while before all end users and fi sh farmers are aware of these changes. This name change does not represent any altera- tions to product names or the contact points within the company. The well established aquaculture Aqua Vac® and Norvax® vaccine ranges, as well as the parasiticide SLICE® and antibiotic Florocol®, continue to be available through their usual sources in the UK. Importantly, the twin focuses of product development and service delivery remain the company’s priorities.


The potenital impact of an outbreak remains significant 43


Vaccination safeguards against mortality, stunted growth and downgrades at processing


Fish Farmer September/October 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52